Abstract:Abstract Background Serological test is helpful in confirming and tracking infectious diseases in large population with the advantage of fast and convenience. Using the specific epitope peptides identified from the whole antigen as the detection antigen is sensitive and relatively economical. The development of epitope peptide-based detection kits for COVID-19 patients requires comprehensive information about epitope peptides. But the data on B cell epitope of SARS-CoV-2 spike protein is still limited. More importantly, there is a lack of serological data on the peptides in the population. In this study, we aimed to identify the B cell epitope peptides of spike protein and detect the reactivity in serum samples, for further providing data support for their subsequent serological applications. Results Two B cell linear epitopes, P104 and P82, located in non-RBD region of SARS-CoV-2 S protein were identified by indirect ELISA screening of an overlapping peptide library of the S protein with COVID-19 patients’ convalescent serum. And the peptides were verified by testing with 165 serum samples. P104 has not been reported previously; P82 is contained in peptide S21P2 reported before. The positive reaction rates of epitope peptides S14P5 and S21P2, the two non-RBD region epitopes identified by Poh et al., and P82 and P104 were 77.0%, 73.9%, 61.2% and 30.3%, respectively, for 165 convalescent sera, including 30 asymptomatic patients. Although P104 had the lowest positive rate for total patients (30.3%), it exhibited slight advantage for detection of asymptomatic infections (36.7%). Combination of epitopes significantly improved the positive reaction rate. Among all combination patterns, (S14P5 + S21P2 + P104) pattern exhibited the highest positive reaction rate for all patients (92.7%), as well as for asymptomatic infections (86.7%), confirming the feasibility of P104 as supplementary antigen for serological detection. In addition, we analyzed the correlation between epitopes with neutralizing antibody, but only S14P5 had a medium positive correlation with neutralizing antibody titre (r s = 0.510, P < 0.01). Conclusion Our research proved that epitopes on non-RBD region are of value in serological detection especially when combination more than one epitope, thus providing serological reaction information about the four epitopes, which has valuable references for their usage.

Seropositive Reaction Rates of 9 B-Cell Epitopes of the SARS-CoV-2 Spike Protein and the Relationship between the Epitopes and Neutralizing Antibody

A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients

Identification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patients.

Novel b-cell epitopes of non-neutralizing antibodies in the receptor-binding domain of the S-protein of SARS-CoV-2 with differing effects on the severity of the course of COVID-19

Functional Mapping of B-cell Linear Epitopes of SARS-CoV-2 in COVID-19 Convalescent Population

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.

Functional Mapping of B-cell Linear Epitopes of SARS-CoV-2 in COVID-19 Convalescent Population.

Dynamics and significance of the antibody response to SARS-CoV-2 infection

Systematic Evaluation of IgG Responses to SARS-CoV-2 Spike Protein-Derived Peptides for Monitoring COVID-19 Patients

Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen

Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID 19 patients

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients

Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients

Three Specific Potential Epitopes That Could Be Recognized by T Cells of Convalescent COVID-19 Patients Were Identified From Spike Protein

Human Post‐infection Serological Response to the Spike and Nucleocapsid Proteins of SARS‐CoV‐2

Longitudinal Immune Profiling Reveals Dominant Epitopes Mediating Long-Term Humoral Immunity in COVID-19–convalescent Individuals

Comparative Analysis of Nucleocapsid Antibody Levels, Neutralizing Antibodies, and Spike Receptor-binding Domain in Severe Acute Respiratory Syndrome Coronavirus-2 Patients

Identification of Three Conserved Linear B Cell Epitopes on the SARS-CoV-2 Spike Protein